top of page

Program

Monday 9 September

09:00

09:15

09:45

09:50​

Session 1: The Tumor Microenvironment, Metastasis and Therapy Resistance

Chair: Therese Sørlie

10:15

10:35

10:40

 

10:50

10:55

11:15

11:20

 

 

11:30

11:35

 

11:55

12:00

13:00

14:00

15:00

Session 2: Risk Stratification, Current and Emerging Treatment regimens

Chair: Gunhild M. Mælandsmo

15:20

 

15:40

15:45

 

 

15:55

16:00

 

 

16:20

16:25

 

 

 

16:35

16:40

 

17:00

17:05

19:00

19:30

Tuesday 10 September

 

Session 3: Norwegian Cancer Research

Chair: Eirik Malinen

09:00

09:20

09:25

 

09:45

09:50

Session 4: Computational and Functional Precision Cancer Medicine
Chair: Leonardo Meza-Zepeda

10:20

10:40

10:45

 

10:55

11:00

11:20

11:30

Session 4: Computational and Functional Precision Medicine - continued

 

12:30

 

 

12:40

12:45

 

13:05

Session 5: Cancer Immunology and Immunotherapy
Chair: Harald Stenmark

13:10

13:30

13:35

 

 

13:45

13:50

14:20

 

14:40

14:45

 

 

14:55

15:00

15:20

15:25

– 09:15

– 09:45

– 09:50

– 10:15

 

 

– 10:35

– 10:40

– 10:50

 

 

– 10:55

– 11:15

– 11:20

– 11:30

 

 

– 11:35

– 11:55

 

– 12:00

– 13:00

– 14:00

– 15:00

– 15:20

 

– 15:40

 

 

– 15:45

– 15:55

 

 

– 16:00

– 16:20

 

 

– 16:25

– 16:35

 

 

 

– 16:40

– 17:00

 

– 17:05

– 19:00

 

 

 

- 09:20

 

 

- 09:25

- 09:45

 

- 09:50

 

- 10:20

- 10:40

- 10:45

- 10:55

 

- 11:00

- 11:20

- 11:25

- 12:30

 

 

- 12:40

 

 

- 12:45

- 13:05

 

- 13:10

- 13:30

- 13:35

- 13:45

 

 

- 13:50

- 14:20

- 14:40

- 14:45

- 14:55

 

 

- 15:00

- 15:20

- 15:25

- 15:30

Opening addresses (Chair: Kjetil Taskén)

Keynote: Douglas Hanahan, Ludwig Institute for Cancer Research and Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland
The Hallmarks of Cancer in 2024

Q&A

Coffee break

 

 

 

Johanna Ivaska, University of Turku, Finland

Pathways limiting cancer progression
Q&A

 

Short talk selected from abstracts: José Teles Reis, Institute for Cancer Research, Oslo University Hospital
Dissecting the mutational drivers behind interclonal interactions in Cancer
Q&A

Erik Sahai, The Francis Crick Institute, London, UK
Mechanisms of resistance to targeted therapy

Q&A

Short talk selected from abstracts: Astrid Medhus, Institute for Cancer Research, Oslo University Hospital
Biomarker guided ADC therapy
Q&A

Verena Jendrossek, University Hospital Essen, Germany
Tumor microenvironment, cancer metabolism and radioresistance

Q&A

Poster session 1, part 1  (Odd-numbered posters)

Lunch

Poster session 1, part 2  (Odd-numbered posters)

Coffee break

Olli Kallioniemi, Karolinska Institutet & SciLifeLab, Stockholm, Sweden
Data-driven Cancer Hallmarks

Q&A


Short talk selected from abstracts: Mev Domingues-Valentin, Institute for Cancer Research, Oslo University Hospital
Towards precision medicine in Lynch Syndrome

Q&A

Sibylle Loibl, Goethe-Universität Frankfurt, Germany
Recent advancement in the treatment of HER2-negative early breast cancer and what biomarkers have taught us

Q&A

Short talk selected from abstracts: Mary-Ann Jallad, Institute for Cancer Research, Oslo University Hospital
High-throughput Combination Drug Screening to Overcome Resistance in Breast Cancer

Q&A

Manuel R Teixeira, IPO Porto, Portugal
Uncovering the missing heritability of prostate cancer

Q&A

Poster session 2  (Even-numbered posters)

Aperitif Reception Area
Banquet Dinner

 

 

 

Per Eystein Lønning, Haukeland University Hospital and University of Bergen, Norway
Prenatal epimutations and cancer risk; a phenomenon affecting a few, or a major risk factor in certain cancer forms?

Q&A

Ragnhild A. Lothe, Institute for Cancer Research, Oslo University Hospital
70-year History of the Institute for Cancer Research

Q&A

Coffee break

Berend Snijder, ETH Zürich, Switzerland
Probing single-cell biology ex vivo for personalized systems medicine

Q&A

Short talk selected from abstracts: Chloe Steen, Institute for Cancer Research, Oslo University Hospital

Pan-cancer Cartography of Human Tumors with CytoSPACE
Q&A

 

Karuna Ganesh, Memorial Sloan Kettering Cancer Centre
Dissecting plasticity during colorectal cancer metastasis

Q&A

Lunch

 

 

Short talk selected from abstracts: Kushtrim Kryeziu, Institute for Cancer Research, Oslo University Hospital
Patient-derived organoids from metastatic colorectal cancer for functional precision oncology

Q&A

 

Anita Sveen, Institute for Cancer Research, Oslo University Hospital
Tumor heterogeneity of treatment response and progression of colorectal cancer

Q&A

Gillian Griffiths, University of Cambridge, UK
Mechanisms of Cytotoxic T-Lymphocyte killing

Q&A

Short talk selected from abstracts: Inga Hansine Rye, Institute for Cancer Research, Oslo University Hospital
Tumor size is key driver of local immunological changes in breast cancer

Q&A

Coffee break

Reuven Agami, The Netherlands Cancer Institute
Amino acid substitutants, cancer development, and anti-tumor immunity

Q&A

Short talk selected from abstracts: Edina Szabo, Institute for Cancer Research, Oslo University Hospital
TIGIT modulates the mitochondrial-metabolism axis and preserves fitness in circulating effector memory T cells

Q&A

 

Johanna Olweus, Institute for Cancer Research, Oslo University Hospital

Opportunities for therapeutic T-cell receptors in cancer immunotherapy

Q&A

Closing words

bottom of page